Literature DB >> 18540493

Managing hypertension using combination therapy.

Jennifer Frank1.   

Abstract

Combination therapy of hypertension with separate agents or a fixed-dose combination pill offers the potential to lower blood pressure more quickly, obtain target blood pressure, and decrease adverse effects. Antihypertensive agents from different classes may offset adverse reactions from each other, such as a diuretic decreasing edema occurring secondary to treatment with a calcium channel blocker. Most patients with hypertension require more than a single antihypertensive agent, particularly if they have comorbid conditions. Although the Joint National Committee guidelines recommend diuretic therapy as the initial pharmacologic agent for most patients with hypertension, the presence of "compelling indications" may prompt treatment with antihypertensive agents that demonstrate a particular benefit in primary or secondary prevention. Specific recommendations include treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, beta blockers, or aldosterone antagonists for hypertensive patients with heart failure. For hypertensive patients with diabetes, recommended treatment includes diuretics, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and/or calcium channel blockers. Recommended treatment for hypertensive patients with increased risk of coronary disease includes a diuretic, beta blockers, angiotensin-converting enzyme inhibitors, and/or calcium channel blocker. The Joint National Committee guidelines recommend beta blockers, angiotensin-converting enzyme inhibitors, and aldosterone antagonists for hypertensive patients who are postmyocardial infarction; angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertensive patients with chronic kidney disease; and diuretic and angiotensin-converting enzyme inhibitors for recurrent stroke prevention in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18540493

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  25 in total

1.  Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure.

Authors:  Selvia M Farag; Hoda M Rabea; Hesham B Mahmoud
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-11-03

2.  Combinatorial therapy discovery using mixed integer linear programming.

Authors:  Kaifang Pang; Ying-Wooi Wan; William T Choi; Lawrence A Donehower; Jingchun Sun; Dhruv Pant; Zhandong Liu
Journal:  Bioinformatics       Date:  2014-01-24       Impact factor: 6.937

3.  Vasorelaxant Effect of a Newly Synthesized Dihydropyridine Ethyl Ester (DHPEE) on Rat Thoracic Aorta: Dual Mechanism of Action.

Authors:  Hossein Babaei; Farzaneh Ebrahimi; Javid Shahbazi Mojarrad; Yadollah Azarmi; Afsaneh Gharehbagheri
Journal:  Adv Pharm Bull       Date:  2011-07-20

4.  Combination of anti-hypertensive drugs: a molecular dynamics simulation study.

Authors:  Abbas Yousefpour; Hamid Modarress; Fatemeh Goharpey; Sepideh Amjad-Iranagh
Journal:  J Mol Model       Date:  2017-04-10       Impact factor: 1.810

Review 5.  Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension.

Authors:  Gregory J Weber; Sathnur Pushpakumar; Suresh C Tyagi; Utpal Sen
Journal:  Pharmacol Res       Date:  2016-09-04       Impact factor: 7.658

6.  Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR.

Authors:  Dénes Páll; Ildikó Szántó; Zoltán Szabó
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

7.  Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016.

Authors:  Catherine G Derington; Jordan B King; Jennifer S Herrick; Daichi Shimbo; Ian M Kronish; Joseph J Saseen; Paul Muntner; Andrew E Moran; Adam P Bress
Journal:  Hypertension       Date:  2020-03-09       Impact factor: 10.190

8.  Physiological regulation of the epithelial Na+ channel by casein kinase II.

Authors:  Jonathan M Berman; Elena Mironova; James D Stockand
Journal:  Am J Physiol Renal Physiol       Date:  2017-10-11

9.  Systems pharmacology and genome medicine: a future perspective.

Authors:  Aislyn D Wist; Seth I Berger; Ravi Iyengar
Journal:  Genome Med       Date:  2009-01-22       Impact factor: 11.117

Review 10.  Deregulation of RGS2 in cardiovascular diseases.

Authors:  Sharon Tsang; Anthony Yiu-Ho Woo; Weizhong Zhu; Rui-Ping Xiao
Journal:  Front Biosci (Schol Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.